Business Advisory Board
CEO of Lodo Therapeutics
In 2019, Dale took the helm at Lodo Therapeutics, which is integrating breakthroughs in next-generation sequencing, artificial intelligence/machine learning and synthetic biology to reinvent natural product-sourced drug discovery and development. His 25 years of experience as a life science entrepreneur, executive and investor include expertise in high technology research tools, genomics, diagnostics and therapeutics.
Dale’s first company, founded while he was in graduate school, was acquired by SmithKline Beckman and launched a laboratory automation still in use today. Since then, he has steered many companies to success. Early in his career, Dale was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE). As founding CEO and Chairman of Orchid BioSciences, a pioneer in genetic analysis and personalized medicine, Dale and his team built the company through strategic acquisitions and took it public in 2000. (NASDAQ: ORCH). Later, he was founding CEO and Chairman of Acuity Pharmaceuticals, an innovative gene-silencing ophthalmology company acquired by OPKO Health (NYSE AMEX: OPK). As CEO of cancer drug developer Receptor BioLogix, Dale prepared the company for acquisition by Danish biotechnology firm Symphogen.
From 2010 until 2019 Dale was the US-based General Partner of the London venture capital firm, Advent Life Sciences. Dale holds a BS degree from the University of California and a PhD in Physics from Brown University.